share_log

杰富瑞上调Moderna(MRNA.US)评级至“买入” 大幅上调目标价至275美元

Jefferies raised the Moderna (MRNA.US) rating to “buy” and raised its target price target to $275

Zhitong Finance ·  Dec 19, 2022 06:26

Jefferies analyst Michael Yee raised its rating on Moderna Inc (MRNA.US) to "buy" from "hold" and sharply raised its target price for the stock to $275 from $170, according to the APP. Yee told investors in a research note that the share price could rebound in 2023, given the opportunities in the company's pipeline line. After the release of positive data from the latest phase II study, he believes that Moderna Inc is a "shiny new thing" in individualized cancer vaccines, and the analyst is also optimistic about Moderna Inc's upcoming data on respiratory syncytial virus phase III. And the franchise of orphans drugs later in 2023.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment